Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has successfully closed its Share Purchase Plan, raising A$4.4 million from shareholders, contributing to a total fundraise of A$12.4 million in conjunction with an earlier institutional placement. These funds will support the advancement of clinical trials and development activities for their Synthetic Anti-Infective products, boosting their cash position to A$19.8 million. The company’s shareholders were fully supportive, with the new shares expected to be issued and quoted on the ASX shortly after the announcement.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
